Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference

BusinessWire_EN 
0 0 01.09.22
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
 

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on September 12, 2022 on Savara’s website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005040/en/

Savara Inc. Stock

€4.06
2.530%
There is an upward development for Savara Inc. compared to yesterday, with an increase of €0.10 (2.530%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Savara Inc. stock is not clear.
With a target price of 5 € there is a positive potential of 23.15% for Savara Inc. compared to the current price of 4.06 €.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!